Pfizer CEO Tests Positive for COVID After Four Shots Because Vaccines Work

Pfizer CEO Albert Bourla announced on Tuesday he had tested positive for COVID-19 despite having received four doses of his company’s vaccine. But don’t worry, he is experiencing “very mild” symptoms, which is proof the shot works.

Bourla, 60, said he is taking Pfizer’s Paxlovid — because that’s what people do when they’re experiencing “very mild symptoms” and want to subject themselves to the very real risk of experiencing rebound COVID.

“I am confident that I will have a speedy recovery,” Bourla said in a statement.

I would like to let you know that I have tested positive for #COVID19. I am thankful to have received four doses of the Pfizer-BioNTech vaccine, and I am feeling well while experiencing very mild symptoms. I am isolating and have started a course of Paxlovid.

— Albert Bourla (@AlbertBourla) August 15, 2022

Pfizer’s COVID-19 vaccine has never been proven to prevent severe disease. That’s just a line parroted by the mainstream media, Biden administration and Pfizer itself to convince the masses they didn’t inject themselves with a lemon.

Several public figures have tested positive for COVID-19 in the past few months including President Joe Biden and chief White House medical advisor Dr. Anthony Fauci. Both received four vaccine doses, tested positive for the virus, took Pfizer’s Paxlovid and then experienced rebound COVID-19.

Instead of isolating themselves for a few days, both had to isolate for more than two weeks.

Pfizer’s COVID-19 vaccine was the first vaccine in the U.S. to receive the privilege of bypassing regulatory standards that ensure a medical product is safe or effective.

In Dec. 2020, the U.S. Food and Drug Administration authorized the Pfizer-BioNTech vaccine for emergency use. It later received full approval in Aug. 2021 for ages 16 and up despite millions of adverse events, including deaths, reported to the Vaccine Adverse Event Reporting System.

Pfizer’s COVID-19 vaccine is now authorized for emergency use in infants and toddlers up to age 5. Boosters have been authorized for ages 5 and older, with a second booster dose authorized for immunocompromised adults age 50 and older.

It apparently made sense to authorize another dose of something that could assault the immune system and was never tested for safety in immunocompromised individuals during clinical trials.

Pfizer is currently working on an updated bivalent COVID-19 booster for the Omicron variant. It will logically be marketed to unsuspecting individuals who still think these shots work.